1
|
Bakkaloğlu SA, Vidal E, Bonthuis M, Neto G, Paripović D, Åsberg A, Hijosa MM, Vondrak K, Jankauskiene A, Roussinov D, Awan A, Jager KJ. European chronic kidney disease registries for children not on kidney replacement therapy: tools for improving health systems and patient-centred outcomes. Clin Kidney J 2023; 16:1980-1985. [PMID: 37915943 PMCID: PMC10616477 DOI: 10.1093/ckj/sfad204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Indexed: 11/03/2023] Open
Abstract
Chronic kidney disease (CKD) in children, from birth to late adolescence, is a unique and highly challenging condition that requires epidemiological research and large-scale, prospective cohort studies. Since its first launch in 2007, the European Society for Paediatric Nephrology/European Renal Association (ESPN/ERA) Registry has collected data on patients on kidney replacement therapy (KRT). However, slowing the progression of CKD is of particular importance and thus the possibility to extend the current registry dataset to include patients in CKD stages 4-5 should be a priority. A survey was sent to the national representatives within the ESPN/ERA Registry to collect information on whether they are running CKD registries. All the representatives from the 38 European countries involved in the ESPN/ERA Registry participated in the survey. Eight existing CKD registries have been identified. General characteristics of the national registry and detailed data on anthropometry, laboratory tests and medications at baseline and at follow-up were collected. Results provided by this survey are highly promising regarding the establishment of an ESPN CKD registry linked to the ESPN/ERA KRT registry and subsequently linking it to the ERA Registry with the same patient identifier, which would allow us to monitor disease progression in childhood and beyond. It is our belief that through such linkages, gaps in patient follow-up will be eliminated and patient-centred outcomes may be improved.
Collapse
Affiliation(s)
- Sevcan A Bakkaloğlu
- Department of Pediatric Nephrology, School of Medicine, Gazi University, Ankara, Turkey
| | - Enrico Vidal
- Pediatric Nephrology Unit, Department for Women's and Children's Health, University Hospital of Padova, Padova, Italy
- Department of Medicine, University of Udine, Udine, Italy
| | - Marjolein Bonthuis
- ESPN/ERA Registry, Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
- Amsterdam Public Health Research Institute, Quality of Care, Amsterdam, The Netherlands
| | - Gisela Neto
- Pediatric Nephrology Unit, Hospital de Dona Estefania, Centro Hospitalar Universitário Lisboa Central, Lisboa, Portugal
| | - Dušan Paripović
- Department of Pediatric Nephrology, School of Medicine, University of Belgrade, University Children's Hospital, Belgrade, Serbia
| | - Anders Åsberg
- Norwegian Renal Registry, Department of Transplantation Medicine, Oslo University Hospital – Rikshospitalet, Oslo, Norway
- Department of Pharmacy, Oslo University, Oslo, Norway
| | | | - Karel Vondrak
- University Hospital Prague, Department of Pediatrics, Children's Hospital Motol, Prague, Czech Republic
| | - Augustina Jankauskiene
- Pediatric Center, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania
| | - Dimitar Roussinov
- Department of Pediatric Nephrology, University Pediatric Hospital, Sofia, Bulgaria
| | - Atif Awan
- Department of Nephrology and Transplantation, Children's Health Ireland and University College Dublin, Dublin, Ireland
| | - Kitty J Jager
- ESPN/ERA Registry, Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
- Amsterdam Public Health Research Institute, Quality of Care, Amsterdam, The Netherlands
- ERA Registry, Department of Medical Informatics, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
| |
Collapse
|
2
|
Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Primers 2021; 7:52. [PMID: 34267223 DOI: 10.1038/s41572-021-00284-z] [Citation(s) in RCA: 468] [Impact Index Per Article: 156.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/09/2021] [Indexed: 02/06/2023]
Abstract
Acute kidney injury (AKI) is defined by a sudden loss of excretory kidney function. AKI is part of a range of conditions summarized as acute kidney diseases and disorders (AKD), in which slow deterioration of kidney function or persistent kidney dysfunction is associated with an irreversible loss of kidney cells and nephrons, which can lead to chronic kidney disease (CKD). New biomarkers to identify injury before function loss await clinical implementation. AKI and AKD are a global concern. In low-income and middle-income countries, infections and hypovolaemic shock are the predominant causes of AKI. In high-income countries, AKI mostly occurs in elderly patients who are in hospital, and is related to sepsis, drugs or invasive procedures. Infection and trauma-related AKI and AKD are frequent in all regions. The large spectrum of AKI implies diverse pathophysiological mechanisms. AKI management in critical care settings is challenging, including appropriate volume control, nephrotoxic drug management, and the timing and type of kidney support. Fluid and electrolyte management are essential. As AKI can be lethal, kidney replacement therapy is frequently required. AKI has a poor prognosis in critically ill patients. Long-term consequences of AKI and AKD include CKD and cardiovascular morbidity. Thus, prevention and early detection of AKI are essential.
Collapse
Affiliation(s)
- John A Kellum
- Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA
| | - Paola Romagnani
- Nephrology and Dialysis Unit, Meyer Children's University Hospital, Florence, Italy
| | - Gloria Ashuntantang
- Faculty of Medicine and Biomedical Sciences, Yaounde General Hospital, University of Yaounde, Yaounde, Cameroon
| | - Claudio Ronco
- Department of Medicine, University of Padova, Padua, Italy.,Department of Nephrology, Dialysis and Kidney Transplant, International Renal Research Institute, San Bortolo Hospital, Vicenza, Italy
| | - Alexander Zarbock
- Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany
| | - Hans-Joachim Anders
- Division of Nephrology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
| |
Collapse
|
3
|
Vanholder R, Rondeau E, Anders HJ, Carlson N, Fliser D, Kanbay M, António Lopes J, Murray PT, Ortiz A, Sanz AB, Selby NM, Wiecek A, Massy ZA. EDTAKI: A Nephrology and Public Policy Committee (NPPC) Platform Call for More European Involvement in AKI. Nephrol Dial Transplant 2021; 37:740-748. [PMID: 33527142 DOI: 10.1093/ndt/gfab018] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Indexed: 01/08/2023] Open
Abstract
Acute Kidney Injury (AKI) is an often neglected but crucial element of clinical nephrology. The aim of the Nephrology Public Policy Committee (NPPC) of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) is to promote several key aspects of European nephrology. One of the targets proposed by NPPC was to advance European nephrology involvement in AKI. We undertook literature analyses to define the current position of European nephrology in the field of AKI compared to other regions, and about how different European countries compare to each other. It appeared that vis-à-vis countries with a comparable socio-economic status (the US, Australia, New Zealand, Canada), the European contribution was almost 50% lower. Within Europe, Central/Eastern Europe and countries with a lower gross domestic product (GDP) showed lower scientific output. Nephrologists contributed to less than half of the output. There was no trend for a change over the last decade. It is concluded that there is room to improve the contribution of European nephrology in the field of AKI. We propose a model on how to promote clinical collaboration on AKI across Europe, the creation of a pan-European nephrology network of interested units is proposed, to improve clinical outcomes, increase nephrologist involvement and awareness outside nephrology, and stimulate research on AKI in Europe. Accordingly, we also propose a list of research priorities and stress the need for more European funding of AKI research.
Collapse
Affiliation(s)
- Raymond Vanholder
- Nephrology Section, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium; European Kidney Health Alliance (EKHA), Brussels, Belgium
| | - Eric Rondeau
- Renal Intensive Care and Transplantation Unit, Hôpital TENON, APHP, Paris; Sorbonne Université, Paris, France
| | - Hans-Joachim Anders
- Division of Nephrology, Department of Medicine IV, University Hospital LMU Munich, Munich, Germany
| | - Nicholas Carlson
- Department of Nephrology, Copenhagen University Hospital Rigshospitalet, Denmark, and Department of Research, The Danish Heart Foundation
| | - Danilo Fliser
- Internal Medicine IV, Saarland University Medical Center, Homburg/Saar, Germany
| | - Mehmet Kanbay
- Nephrology Section, Department of Internal Medicine, Koc University School of Medicine, Istanbul, Turkey
| | - José António Lopes
- Division of Nephrology and Renal Transplantation, Centro Hospitalar Universitário Lisboa Norte, Av. Prof. Egas Moniz, 1649-035, Lisboa, Portugal
| | - Patrick T Murray
- School of Medicine, University College Dublin, UCD Catherine McAuley Education & Research Centre, Eccles Street, Dublin 7, Ireland
| | - Alberto Ortiz
- Research Institute Fundacion Jemenez Diaz, Autonoma University Madrid, Spain
| | - Ana B Sanz
- Research Institute Fundacion Jemenez Diaz, Autonoma University Madrid, Spain
| | - Nicholas M Selby
- Centre for Kidney Research and Innovation, Division of Health Sciences and Graduate Entry Medicine, University of Nottingham, UK
| | - Andrzej Wiecek
- Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia in Katowice, Poland
| | - Ziad A Massy
- Department of Nephrology, Ambroise Paré University Hospital, APHP, Boulogne-Billancourt/Paris, and Centre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Versailles Saint Quentin University, INSERM UMRS 1018, Team5 Villejuif, France
| |
Collapse
|
4
|
Vanholder R, Argilés A, Jankowski J. A history of uraemic toxicity and of the European Uraemic Toxin Work Group (EUTox). Clin Kidney J 2021; 14:1514-1523. [PMID: 34413975 PMCID: PMC8371716 DOI: 10.1093/ckj/sfab011] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Indexed: 12/13/2022] Open
Abstract
The uraemic syndrome is a complex clinical picture developing in the advanced stages of chronic kidney disease, resulting in a myriad of complications and a high early mortality. This picture is to a significant extent defined by retention of metabolites and peptides that with a preserved kidney function are excreted or degraded by the kidneys. In as far as those solutes have a negative biological/biochemical impact, they are called uraemic toxins. Here, we describe the historical evolution of the scientific knowledge about uraemic toxins and the role played in this process by the European Uraemic Toxin Work Group (EUTox) during the last two decades. The earliest knowledge about a uraemic toxin goes back to the early 17th century when the existence of what would later be named as urea was recognized. It took about two further centuries to better define the role of urea and its link to kidney failure, and one more century to identify the relevance of post-translational modifications caused by urea such as carbamoylation. The knowledge progressively extended, especially from 1980 on, by the identification of more and more toxins and their adverse biological/biochemical impact. Progress of knowledge was paralleled and impacted by evolution of dialysis strategies. The last two decades, when insights grew exponentially, coincide with the foundation and activity of EUTox. In the final section, we summarize the role and accomplishments of EUTox and the part it is likely to play in future action, which should be organized around focus points like biomarker and potential target identification, intestinal generation, toxicity mechanisms and their correction, kidney and extracorporeal removal, patient-oriented outcomes and toxin characteristics in acute kidney injury and transplantation.
Collapse
Affiliation(s)
- Raymond Vanholder
- Department of Internal Medicine and Pediatrics, Nephrology Section, Ghent University Hospital, Ghent, Belgium
| | - Angel Argilés
- RD-Néphrologie, Montpellier, France.,Néphrologie Dialyse St Guilhem, Sète, France
| | - Joachim Jankowski
- Institute for Molecular Cardiovascular Research, University Hospital, RWTH Aachen, Aachen, Germany.,School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands
| | | |
Collapse
|
5
|
Sever MŞ, Jager KJ, Vanholder R, Stengel B, Harambat J, Finne P, Tesař V, Barbullushi M, Bumblytė IA, Zakharova E, Spasovski G, Resic H, Wiecek A, Blankestijn PJ, Bruchfeld A, Cozzolino M, Goumenos D, Soler MJ, Rychlík I, Stevens KI, Wanner C, Zoccali C, Massy ZA. A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. Clin Kidney J 2021; 14:23-35. [PMID: 33570513 PMCID: PMC7857792 DOI: 10.1093/ckj/sfaa218] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 09/08/2020] [Indexed: 12/23/2022] Open
Abstract
Chronic kidney disease (CKD) is a major health problem because of its high prevalence, associated complications and high treatment costs. Several aspects of CKD differ significantly in the Eastern European nephrology community compared with Western Europe because of different geographic, socio-economic, infrastructure, cultural and educational features. The two most frequent aetiologies of CKD, DM and hypertension, and many other predisposing factors, are more frequent in the Eastern region, resulting in more prevalent CKD Stages 3-5. Interventions may minimize the potential drawbacks of the high prevalence of CKD in Eastern Europe, which include several options at various stages of the disease, such as raising public, medical personnel and healthcare authorities awareness; early detection by screening high-risk populations; preventing progression and CKD-related complications by training health professionals and patients; promoting transplantation or home dialysis as the preferred modality; disseminating and implementing guidelines and guided therapy and encouraging/supporting country-specific observational research as well as international collaborative projects. Specific ways to significantly impact CKD-related problems in every region of Europe through education, science and networking are collaboration with non-nephrology European societies who have a common interest in CKD and its associated complications, representation through an advisory role within nephrology via national nephrology societies, contributing to the training of local nephrologists and stimulating patient-oriented research. The latter is mandatory to identify country-specific kidney disease-related priorities. Active involvement of patients in this research via collaboration with the European Kidney Patient Federation or national patient federations is imperative to ensure that projects reflect specific patient needs.
Collapse
Affiliation(s)
- Mehmet Şükrü Sever
- Department of Nephrology, Istanbul School of Medicine, Istanbul University, Istanbul, Turkey
| | - Kitty J Jager
- ERA-EDTA Registry, Department of Medical Informatics, Amsterdam Public Health Research Institute Amsterdam, Noord-Holland, The Netherlands
| | - Raymond Vanholder
- Nephrology Section, Department of Internal Medicine and Pediatrics, University Hospital Ghent, Gent, Belgium
- European Kidney Health Alliance (EKHA), Brussels, Belgium
| | - Benedicte Stengel
- UVSQ, University Paris-Saclay, University Paris-Sud, Inserm, Clinical Epidemiology Team, CESP, Villejuif, France
| | - Jerome Harambat
- Pediatric Nephrology Unit, Bordeaux University Hospital, Bordeaux, France
- University of Bordeaux, INSERM U1219, Bordeaux, France
| | - Patrik Finne
- Helsinki University Central Hospital, Division of Nephrology, Helsinki, 00029, Finland
| | - Vladimir Tesař
- Department of Nephrology, General University Hospital, Charles University, Prague 12808, Czech Republic
| | | | - Inga A Bumblytė
- Nephrology Department, Faculty of Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - Elena Zakharova
- Nephrology Unit, City Clinical Hospital n.a. s.P. Botkin, 2-nd Botkinsky proezd 5, Moscow, Russia
| | - Goce Spasovski
- Department of Nephrology, University “Sts. Cyril and Methodius”, Vodnjanska 17 Skopje, MK, Republic of Macedonia
| | - Halima Resic
- Society of Nephrology of Bosnia and Herzegovina, Clinic for Hemodialysis Sarajevo, Clinical Center University of Sarajevo, BA, Bosnia-Herzegovina
| | - Andrzej Wiecek
- Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland
| | - Peter J Blankestijn
- Department of Nephrology, University Medical Center, Utrecht, Utrecht, The Netherlands
| | - Annette Bruchfeld
- Department of Health, Medicine and Caring Sciences, Linköping University, Faculty of Medicine, Linköping, Sweden
- Department of Renal Medicine, Karolinska University Hospital, CLINTEC KI, Stockholm, SE 141 86, Sweden
| | - Mario Cozzolino
- University of Milan, Health Sciences via di rudinì 8 Milano, Lombardia, IT 20122, Italy
| | - Dimitris Goumenos
- Department of Nephrology, Patras University Hospital, Rio 265 04, Patras, Greece
| | - Maria Jose Soler
- Department of Nephrology, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
| | - Ivan Rychlík
- Department of Medicine, Third Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady,Prague, Czech Republic
| | - Kate I Stevens
- The Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, G51 4TF, UK
| | - Christoph Wanner
- Division of Nephrology, University Hospital Würzburg, Oberdürrbacherstr. 6, Würzburg 97080, Germany
| | - Carmine Zoccali
- IFC Sezione di Reggio Calabria CNR, Clinical Epidemiology of Renal Diseases and Hypertension Reggio Calabria, Calabria, Italy
| | - Ziad A Massy
- Division of Nephrology, Ambroise Paré University Hospital, APHP, University of Paris Ouest-Versailles-St-Quentin-en-Yvelines (UVSQ) av G De Gaulles Boulogne-Billancourt/Paris, x, FR 92100; Inserm U1018, CESP Team 5-Epidemiology of Renal and Cardiovascular Disease, Villejuif, France
| |
Collapse
|
6
|
Carriazo S, Ortiz A. European East-West divide in kidney disease: the need to understand the drivers of chronic kidney disease outcomes. Clin Kidney J 2021; 14:1-4. [PMID: 33564399 PMCID: PMC7857834 DOI: 10.1093/ckj/sfaa217] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Accepted: 09/08/2020] [Indexed: 01/02/2023] Open
Abstract
In this issue of ckj, Sever et al. (A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community. Clin Kidney J, this issue) present a roadmap for optimizing chronic kidney disease (CKD) patient care and patient-oriented research in Eastern Europe. The document clearly identifies current unmet needs and proposes corrective actions. Focusing on CKD epidemiology and outcomes, it collects evidence pointing to an East-West gradient for some key risk factors for CKD development. Thus, the prevalence of diabetes, raised blood pressure, obesity and tobacco use is higher in Eastern than in Western Europe. These risk factors may contribute to the higher CKD prevalence in Eastern Europe, which for the Eastern-most countries may be more than 2-fold higher than in Western Europe. The problem is compounded by the lower prevalence of dialysis and transplantation in Eastern Europe, especially in lower income countries. The combination of higher prevalence of CKD with lower prevalence of renal replacement therapy would be expected to result in higher CKD-associated mortality, but this is not the case. CKD-associated mortality may even be lower in the Eastern-most European countries than in Western Europe. The reasons for this discrepancy should be studied, since it may reveal serious additional healthcare issues, potentially related to high mortality from other non-communicable diseases (NCDs). If this is the case and the high mortality from other NCD is successfully addressed, pressure will further mount on renal replacement capacity needs in Eastern Europe.
Collapse
Affiliation(s)
- Sol Carriazo
- IIS-Fundación Jiménez Diaz, Department of Medicine, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
- Red de Investigación Renal (REDINREN), Madrid, Spain
| | - Alberto Ortiz
- IIS-Fundación Jiménez Diaz, Department of Medicine, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
- Red de Investigación Renal (REDINREN), Madrid, Spain
| |
Collapse
|
7
|
Abstract
The development of dialysis by early pioneers such as Willem Kolff and Belding Scribner set in motion several dramatic changes in the epidemiology, economics and ethical frameworks for the treatment of kidney failure. However, despite a rapid expansion in the provision of dialysis — particularly haemodialysis and most notably in high-income countries (HICs) — the rate of true patient-centred innovation has slowed. Current trends are particularly concerning from a global perspective: current costs are not sustainable, even for HICs, and globally, most people who develop kidney failure forego treatment, resulting in millions of deaths every year. Thus, there is an urgent need to develop new approaches and dialysis modalities that are cost-effective, accessible and offer improved patient outcomes. Nephrology researchers are increasingly engaging with patients to determine their priorities for meaningful outcomes that should be used to measure progress. The overarching message from this engagement is that while patients value longevity, reducing symptom burden and achieving maximal functional and social rehabilitation are prioritized more highly. In response, patients, payors, regulators and health-care systems are increasingly demanding improved value, which can only come about through true patient-centred innovation that supports high-quality, high-value care. Substantial efforts are now underway to support requisite transformative changes. These efforts need to be catalysed, promoted and fostered through international collaboration and harmonization. Dialysis is a life-saving therapy; however, costs of dialysis are high, access is inequitable and outcomes are inadequate. This Review describes the current landscape of dialysis therapy from an epidemiological, economic, ethical and patient-centred framework, and describes initiatives that are aimed at stimulating innovations in the field to one that supports high-quality, high-value care. The global dialysis population is growing rapidly, especially in low-income and middle-income countries; however, worldwide, a substantial number of people lack access to kidney replacement therapy, and millions of people die of kidney failure each year, often without supportive care. The costs of dialysis care are high and will likely continue to rise as a result of increased life expectancy and improved therapies for causes of kidney failure such as diabetes mellitus and cardiovascular disease. Patients on dialysis continue to bear a high burden of disease, shortened life expectancy and report a high symptom burden and a low health-related quality of life. Patient-focused research has identified fatigue, insomnia, cramps, depression, anxiety and frustration as key symptoms contributing to unsatisfactory outcomes for patients on dialysis. Initiatives to transform dialysis outcomes for patients require both top-down efforts (that is, efforts that promote incentives based on systems level policy, regulations, macroeconomic and organizational changes) and bottom-up efforts (that is, patient-led and patient-centred advocacy efforts as well as efforts led by individual teams of innovators). Patients, payors, regulators and health-care systems increasingly demand improved value in dialysis care, which can only come about through true patient-centred innovation that supports high-quality, high-value care.
Collapse
|